SRR650150
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.320
- MYC_TARGETS_V2+0.300
- SPERMATOGENESIS+0.120
- PANCREAS_BETA_CELLS+0.060
- E2F_TARGETS+0.030
- APICAL_SURFACE+0.010
- HEDGEHOG_SIGNALING+0.000
- ESTROGEN_RESPONSE_LATE-0.050
- MYOGENESIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.130
Top 10 suppressed
- PROTEIN_SECRETION-0.590
- INTERFERON_ALPHA_RESPONSE-0.510
- TGF_BETA_SIGNALING-0.490
- INTERFERON_GAMMA_RESPONSE-0.470
- ANDROGEN_RESPONSE-0.450
- IL6_JAK_STAT3_SIGNALING-0.440
- APOPTOSIS-0.430
- UV_RESPONSE_DN-0.420
- COMPLEMENT-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195643 | — | — | 0.947 |
| 2 | SRR650166 | — | — | 0.945 |
| 3 | SRR1797291 | — | cohortSC | 0.945 |
| 4 | TCGA-KQ-A41O-01A-12R-A352-07 | — | — | 0.936 |
| 5 | sclc265549_S73.txt | — | cohortMD1 | 0.935 |
| 6 | SRR12202488 | — | — | 0.927 |
| 7 | BS_77317DY4 | medulloblastoma | — | 0.926 |
| 8 | SRR650159 | — | — | 0.923 |
| 9 | MNG459 | — | — | 0.922 |
| 10 | SRR1467813 | GTEX | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.320 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.030 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |